Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

Dr Neil Torbett Promoted CEO of PhoreMost

Founder and former CEO, Dr Chris Torrance, appointed to Chair

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Dr Neil Torbett was previously the Company’s Chief Operating Officer. Founder and former CEO, Dr Chris Torrance will become Chair of the Board.

Dr Neil Torbett joined PhoreMost as Chief Business Officer in January 2017 and was promoted to Chief Operating Officer in 2020, holding responsibility for all operational, scientific and commercial activities. During this period, the Company has made significant progress across its internal first-in-class drug discovery programmes, focussing on Oncology and Targeted Protein Degradation, along with its portfolio of high-value research collaborations.

In addition, the Company completed an oversubscribed £33M Series B investment round, one of the largest private fund-raises within UK life sciences in 2021. This year, PhoreMost relocated its headquarters and laboratory space to a new state-of-the-art facility in South Cambridge in order to accommodate the Company’s accelerated expansion and ongoing recruitment efforts.

Neil has over 16 years of research and management experience in the biotechnology industry. Prior to PhoreMost, Neil co-founded Activiomics Ltd, a proteomics spin-out from Bart’s Cancer Institute, where he served as Chief Operating Officer until its acquisition by Retroscreen Virology (now hVIVO) in 2014. He has also worked at Piramed Pharma, where he was involved in the management of a successful cancer research collaboration with Genentech. Neil completed his PhD at the Protein Phosphorylation laboratory at the Cancer Research UK London Research Institute, with postdoctoral training at the University of California San Francisco Cancer Centre.

As Chair of PhoreMost’s Board, Dr Torrance will continue to focus on strategic initiatives for PhoreMost, working closely with Dr Torbett and the leadership team to drive expansion of its next-generation SITESEEKER® target discovery platform and guide the development of the Company’s drug discovery programmes.

Dr Neil Torbett, CEO, PhoreMost said: “It is a privilege to be granted the opportunity to support the amazing team at PhoreMost as their CEO. I am very excited about the opportunities we have in 2022 to advance our pipeline of novel Oncology and Degrader-based therapeutics. I would also like to thank Chris for his inspirational leadership, and I look forward to continuing our partnership in pursuit of PhoreMost’s mission to open up new druggable space.”

Dr Chris Torrance, Chair of PhoreMost, commented: “Neil’s invaluable expertise and guidance as COO has been key to PhoreMost’s great progress over the last few years. He is a huge asset to the Company and as CEO, I know that he will continue to shape PhoreMost as a fully integrated target identification and drug discovery company – I look forward to a continued working relationship with Neil in my role as Chair. My sincere thanks also go to outgoing Chair, Catherine Beech for her pivotal role in positioning PhoreMost at the forefront of new wave of companies “Drugging the Undruggable®.”

Dr Catherine Beech OBE, PhoreMost board member and outgoing Chair, added: “We would like to thank Chris for his leadership of PhoreMost since he founded the Company in 2014, establishing an exceptional team that is both science-driven and entrepreneurial in nature. With his guidance, PhoreMost has achieved impressive milestones across its internal drug discovery programmes and portfolio of high-value research collaborations. We look forward to working with both Chris and Neil in their new roles, to drive the next phase of the Company’s growth and continued success.”

 

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine